{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:35:22Z","timestamp":1791362122921,"version":"4.3.1"},"reference-count":176,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The incidence and mortality of cancer have increased over the past decades. Significant progress has been made in understanding the underpinnings of this disease and developing therapies. Despite this, cancer still remains a major therapeutic challenge. Current therapeutic research has targeted several aspects of the disease such as cancer development, growth, angiogenesis and metastases. Many molecular and cellular mechanisms remain unknown and current therapies have so far failed to meet their intended potential. Recent studies show that glycans, especially oligosaccharide chains, may play a role in carcinogenesis as recognition patterns for galectins. Galectins are members of the lectin family, which show high affinity for \u03b2-galactosides. The galectin\u2013glycan conjugate plays a fundamental role in metastasis, angiogenesis, tumor immunity, proliferation and apoptosis. Galectins\u2019 action is mediated by a structure containing at least one carbohydrate recognition domain (CRD). The potential prognostic value of galectins has been described in several neoplasms and helps clinicians predict disease outcome and determine therapeutic interventions. Currently, new therapeutic strategies involve the use of inhibitors such as competitive carbohydrates, small non-carbohydrate binding molecules and antibodies. This review outlines our current knowledge regarding the mechanism of action and potential therapy implications of galectins in cancer.<\/jats:p>","DOI":"10.3390\/ijms19010210","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T12:41:10Z","timestamp":1515588070000},"page":"210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-4245","authenticated-orcid":false,"given":"Kamil","family":"Wdowiak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Oncology, Silesian Medical University, Katowice 40-027, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Francuz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Silesian Medical University, Katowice 40-027, Poland"},{"name":"Department of Biochemistry, Silesian Medical University, Katowice 40-752, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-6464","authenticated-orcid":false,"given":"Enrique","family":"Gallego-Colon","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Silesian Medical University, Katowice 40-752, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ruiz-Agamez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Silesian Medical University, Katowice 40-752, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kubeczko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Silesian Medical University, Katowice 40-027, Poland"},{"name":"Clinical and Experimental Oncology Department, Maria Sk\u0142odowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice 44-101, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iga","family":"Grocho\u0142a","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Silesian Medical University, Katowice 40-027, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Wojnar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Silesian Medical University, Katowice 40-027, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbcan.2015.03.003","article-title":"Galectin expression in cancer diagnosis and prognosis: A systematic review","volume":"1855","author":"Thijssen","year":"2015","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1535370215593826","article-title":"Galectin-3 in autoimmunity and autoimmune diseases","volume":"240","author":"Gatto","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20807","DOI":"10.1016\/S0021-9258(17)31891-4","article-title":"Galectins. Structure and function of a large family of animal lectins","volume":"269","author":"Barondes","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e29380","DOI":"10.4161\/onci.29380","article-title":"Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis","volume":"3","author":"Croci","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4049\/jimmunol.176.2.778","article-title":"Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death","volume":"176","author":"Stillman","year":"2006","journal-title":"J. Immunol."},{"key":"ref_6","first-page":"8302","article-title":"CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis","volume":"63","author":"Fukumori","year":"2003","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0304-4165(02)00311-2","article-title":"Oligosaccharide specificity of galectins: A search by frontal affinity chromatography","volume":"1572","author":"Hirabayashi","year":"2002","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1111\/j.1742-4658.2010.07764.x","article-title":"Tumor suppressor p16INK4a: Downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model","volume":"277","author":"Fischer","year":"2010","journal-title":"FEBS J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1158\/0008-5472.CAN-05-0775","article-title":"Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells","volume":"65","author":"Cooks","year":"2005","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1074\/jbc.270.10.5207","article-title":"Galectin-1, a \u03b2-galactoside-binding lectin in Chinese hamster ovary cells: II. Localization and biosynthesis","volume":"270","author":"Cho","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2353\/ajpath.2008.070938","article-title":"The galectin profile of the endothelium","volume":"172","author":"Thijssen","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ijc.10843","article-title":"Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration","volume":"103","author":"Hittelet","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.1002940","article-title":"Lung Cancer-Derived galectin-1 Mediates Dendritic Cell Anergy through Inhibitor of DNA Binding 3\/IL-10 Signaling Pathway","volume":"186","author":"Kuo","year":"2011","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/0008-5472.CAN-12-2418","article-title":"Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease","volume":"73","author":"Croci","year":"2013","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4161\/cbt.20842","article-title":"Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma","volume":"13","author":"Chen","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/ijc.26290","article-title":"High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer","volume":"130","author":"Tang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2119\/molmed.2009.00119","article-title":"Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness","volume":"16","author":"Spano","year":"2010","journal-title":"Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000326006","article-title":"Proteomic identification of new biomarkers and application in thyroid cytology","volume":"50","author":"Bibbo","year":"2006","journal-title":"Acta Cytol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/1078-0432.CCR-09-2765","article-title":"MLL-Rearranged B Lymphoblastic Leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1","volume":"16","author":"Juszczynski","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_20","first-page":"119","article-title":"The involvement of galectins in the modulation of the JAK\/STAT pathway in myeloproliferative neoplasia","volume":"2","author":"Koopmans","year":"2012","journal-title":"Am. J. Blood Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2007.0361","article-title":"Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease","volume":"18","author":"Saussez","year":"2008","journal-title":"Thyroid"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood-2011-12-396457","article-title":"Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma","volume":"119","author":"Watanabe","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-013-1201-8","article-title":"Altered galectin-1 serum levels in patients diagnosed with high-grade glioma","volume":"115","author":"Verschuere","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1128\/MCB.17.8.4730","article-title":"Evidence for a role for galectin-1 in pre-mRNA splicing","volume":"17","author":"Vyakarnam","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Astorgues-Xerri, L., Riveiro, M.E., Tijeras-Raballand, A., Serova, M., Neuzillet, C., Albert, S., Raymond, E., and Faivre, S. (2014). Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treatment Reviews, Elsevier Ltd.","DOI":"10.1016\/j.ctrv.2013.07.007"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7486","DOI":"10.1038\/sj.onc.1204950","article-title":"Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation","volume":"20","author":"Paz","year":"2001","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.4049\/jimmunol.178.3.1573","article-title":"Necrotic tumor cell death in vivo impairs tumor-specific immune responses","volume":"178","author":"Gamrekelashvili","year":"2007","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.13-S3-21","article-title":"Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis","volume":"13","author":"Vaupel","year":"2008","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/carcin\/bgq116","article-title":"Hypoxia inducible factor-1 mediates expression of galectin-1: The potential role in migration\/invasion of colorectal cancer cells","volume":"31","author":"Zhao","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1200\/JCO.2005.02.0206","article-title":"Galectin-1: A link between tumor hypoxia and tumor immune privilege","volume":"23","author":"Le","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10456-011-9213-5","article-title":"Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress","volume":"14","author":"Ito","year":"2011","journal-title":"Angiogenesis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10585-012-9471-7","article-title":"Inhibiting galectin-1 reduces murine lung metastasis with increased CD4+ and CD8+ T cells and reduced cancer cell adherence","volume":"29","author":"Ito","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10555-012-9388-2","article-title":"Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment","volume":"31","author":"Ito","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"ref_34","first-page":"8890","article-title":"Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects","volume":"63","author":"Abdollahi","year":"2003","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization","volume":"13","author":"Dings","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2009.05.021","article-title":"Anti-angiogenesis and anti-tumor effects of AdNT4-anginex","volume":"285","author":"Dong","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.112.199646","article-title":"Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1","volume":"344","author":"Dings","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13801","DOI":"10.1074\/jbc.C111.229096","article-title":"The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins","volume":"286","author":"Salomonsson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/jm300014q","article-title":"Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding","volume":"55","author":"Dings","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djj247","article-title":"Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities","volume":"98","author":"Dings","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.canlet.2008.02.048","article-title":"Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven","volume":"265","author":"Dings","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00280-013-2270-2","article-title":"Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib","volume":"72","author":"Zucchetti","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejmech.2014.10.048","article-title":"Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation","volume":"89","author":"Dings","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1084\/jem.20111665","article-title":"Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi\u2019s sarcoma","volume":"209","author":"Croci","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/glycob\/cwp084","article-title":"The \u03b1-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain","volume":"19","author":"Miller","year":"2009","journal-title":"Glycobiology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/bk-2012-1102.ch004","article-title":"DAVANAT\u00ae (GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies","volume":"Volume 1102","author":"Klyosov","year":"2012","journal-title":"Glycobiology and Drug Design"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3540233","article-title":"Anginex, a designed peptide that inhibits angiogenesis","volume":"354","author":"Griffioen","year":"2001","journal-title":"Biochem. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.peptides.2012.09.007","article-title":"Peptides Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent","volume":"38","author":"Ju","year":"2012","journal-title":"Peptides"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15975","DOI":"10.1073\/pnas.0603883103","article-title":"Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy","volume":"103","author":"Thijssen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-09-4150","article-title":"Tumor cells secrete galectin-1 to enhance endothelial cell activity","volume":"70","author":"Thijssen","year":"2010","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10147-006-0625-y","article-title":"Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay","volume":"12","author":"Amano","year":"2007","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_52","first-page":"3374","article-title":"Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ijc.20850","article-title":"Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells","volume":"115","author":"Dings","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_54","first-page":"382","article-title":"The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin","volume":"63","author":"Dings","year":"2003","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.bbrc.2005.06.029","article-title":"Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein","volume":"333","author":"Brandwijk","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/bc060316h","article-title":"Anginex-Conjugated liposomes for targeting of angiogenic endothelial cells","volume":"18","author":"Brandwijk","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1021\/bc900287y","article-title":"Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene","volume":"21","author":"Dings","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"41559","DOI":"10.18632\/oncotarget.9490","article-title":"Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer","volume":"7","author":"Upreti","year":"2016","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"45746","DOI":"10.1074\/jbc.M308608200","article-title":"Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity","volume":"278","author":"Mayo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.ejca.2014.06.015","article-title":"OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis","volume":"50","author":"Riveiro","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.21873\/anticanres.11074","article-title":"Inhibition of galectin-1 sensitizes hras-driven tumor growth to rapamycin treatment","volume":"36","author":"Michael","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s10637-013-9932-0","article-title":"Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer","volume":"31","author":"Dings","year":"2013","journal-title":"Invest. New Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1158\/1078-0432.CCR-13-2459","article-title":"A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes","volume":"20","author":"Demotte","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/jid.2011.335","article-title":"Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity","volume":"132","author":"Opperman","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/sj.jid.5700869","article-title":"Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model","volume":"127","author":"Mathieu","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2326-6066.CIR-16-0385","article-title":"Combined Anti-VEGF and Anti\u2013CTLA-4 therapy elicits humoral immunity to Galectin-1 which is associated with favorable clinical outcomes","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Traber, P.G., and Zomer, E. (2013). Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083481"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ejca.2011.09.003","article-title":"Association of galectin-3 expression with melanoma progression and prognosis","volume":"48","author":"Brown","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/CMR.0b013e32832ec001","article-title":"Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients","volume":"19","author":"Vereecken","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.2005.01992.x","article-title":"High serum galectin-3 in advanced melanoma: Preliminary results","volume":"31","author":"Vereecken","year":"2006","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10555-013-9450-8","article-title":"Why anti-Bcl-2 clinical trials fail: A solution","volume":"33","author":"Harazono","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/B:GLYC.0000014072.34840.04","article-title":"Introduction to galectins","volume":"19","author":"Leffler","year":"2002","journal-title":"Glycoconj. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1432-1327.1999.00671.x","article-title":"Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum\u2013Golgi complex","volume":"264","author":"Menon","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.2174\/09298673113209990163","article-title":"Human galectin-3 selective and high affinity inhibitors. Present state and future perspectives","volume":"20","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","article-title":"Galectin-3\u2014A jack-of-all-trades in cancer","volume":"313","author":"Newlaczyl","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(00)04817-0","article-title":"Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions","volume":"357","author":"Bartolazzi","year":"2001","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(08)70132-3","article-title":"Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: A prospective multicentre study","volume":"9","author":"Bartolazzi","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PAI.0b013e31821ee9bb","article-title":"Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules","volume":"20","author":"Bartolazzi","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Trimboli, P., Virili, C., Romanelli, F., Crescenzi, A., and Giovanella, L. (2017). Galectin-3 performance in histologic and cytologic assessment of thyroid nodules: A systematic review and Meta-analysis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081756"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbamcr.2015.08.008","article-title":"Galectin 3 as a guardian of the tumor microenvironment","volume":"1863","author":"Ruvolo","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1038\/sj.onc.1205820","article-title":"Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells","volume":"21","author":"Lin","year":"2002","journal-title":"Oncogene"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1158\/0008-5472.CAN-05-0104","article-title":"Implication of galectin-3 in Wnt signaling","volume":"65","author":"Shimura","year":"2005","journal-title":"Cancer Res."},{"key":"ref_84","first-page":"5272","article-title":"Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family","volume":"57","author":"Akahani","year":"1997","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"34922","DOI":"10.1074\/jbc.M312697200","article-title":"Galectin-3 augments K-ras activation and triggers a ras signal that attenuates ERK but not phosphoinositide 3-kinase activity","volume":"279","author":"Haklai","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Veschi, V., Petroni, M., Cardinali, B., Dominici, C., Screpanti, I., Frati, L., Bartolazzi, A., Gulino, A., and Giannini, G. (2012). Galectin-3 impairment of MYCN-Dependent apoptosis-sensitive phenotype is antagonized by Nutlin-3 in Neuroblastoma cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049139"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.febslet.2013.10.034","article-title":"Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45","volume":"587","author":"Xue","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"33311","DOI":"10.1074\/jbc.M114.603464","article-title":"Tumor-released galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack","volume":"289","author":"Wang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1158\/0008-5472.CAN-05-3750","article-title":"Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer","volume":"66","author":"Fukumori","year":"2006","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drup.2007.04.001","article-title":"The role of galectin-3 in cancer drug resistance","volume":"10","author":"Fukumori","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"19592","DOI":"10.18632\/oncotarget.4285","article-title":"Extracellular galectin-3 programs multidrug resistance through Na+\/K+-ATPase and P-glycoprotein signaling","volume":"6","author":"Harazono","year":"2015","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1158\/0008-5472.CAN-05-0163","article-title":"A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells","volume":"65","author":"Chauhan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-012-9516-y","article-title":"Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide","volume":"30","author":"Dickerson","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.biomaterials.2011.12.007","article-title":"Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3\u2013C12)-5-Fluorouracil conjugates","volume":"33","author":"Yang","year":"2012","journal-title":"Biomaterials"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1021\/mp500083u","article-title":"Targeting prostate carcinoma by G3\u2013C12 peptide conjugated N-(2-hydroxypropyl)methacrylamide copolymers","volume":"11","author":"Yang","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1021\/am509204u","article-title":"Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer","volume":"7","author":"Yang","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1021\/acs.molpharmaceut.5b00568","article-title":"G3\u2013C12 peptide reverses galectin-3 from foe to friend for active targeting cancer treatment","volume":"12","author":"Sun","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1534735410369672","article-title":"PectaSol-C Modified Citrus Pectin Induces Apoptosis and Inhibition of Proliferation in Human and Mouse Androgen-Dependent and -Independent Prostate Cancer Cells","volume":"9","author":"Yan","year":"2010","journal-title":"Integr. Cancer Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0002-9440(10)64959-0","article-title":"Galectin-3 induces endothelial cell morphogenesis and angiogenesis","volume":"156","author":"Honjo","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/jnci\/94.24.1854","article-title":"Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin","volume":"94","author":"Hogan","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"CMO.S285","DOI":"10.4137\/CMO.S285","article-title":"Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study","volume":"1","author":"Hildenbrand","year":"2007","journal-title":"Clin. Med. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1158\/0008-5472.CAN-10-0761","article-title":"A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice","volume":"70","author":"Demotte","year":"2010","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/CBI20110309","article-title":"Combination effect of PectaSol and Doxorubicin on viability, cell cycle arrest and apoptosis in DU-145 and LNCaP prostate cancer cell lines","volume":"36","author":"Tehranian","year":"2012","journal-title":"Cell Biol. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.7314\/APJCP.2013.14.12.7561","article-title":"Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells","volume":"14","author":"Hossein","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death","volume":"115","author":"Streetly","year":"2010","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1038\/cddis.2010.79","article-title":"Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment","volume":"1","author":"Wang","year":"2010","journal-title":"Cell Death Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-438234","article-title":"Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death","volume":"120","author":"Clark","year":"2012","journal-title":"Blood"},{"key":"ref_108","first-page":"562","article-title":"Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells","volume":"1863","author":"Ruvolo","year":"2015","journal-title":"BBA Mol. Cell Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/jco.2009.27.15_suppl.7006","article-title":"Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia","volume":"27","author":"Cotter","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/tra.12086","article-title":"pH-Dependent recycling of galectin-3 at the apical membrane of Epithelial cells","volume":"14","author":"Straube","year":"2013","journal-title":"Traffic"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.biopha.2008.07.058","article-title":"Citrus pectin affects cytokine production by human peripheral blood mononuclear cells","volume":"62","author":"Salman","year":"2008","journal-title":"Biomed. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.tifs.2015.04.001","article-title":"Pectin in cancer therapy: A review","volume":"44","author":"Zhang","year":"2015","journal-title":"Trends Food Sci. Technol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/B:GLYC.0000025819.54723.a0","article-title":"Galectin-4 in normal tissues and cancer","volume":"20","author":"Huflejt","year":"2003","journal-title":"Glycoconj. J."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Hayashi, T., Saito, T., Fujimura, T., Hara, K., Takamochi, K., Mitani, K., Mineki, R., Kazuno, S., Oh, S., and Ueno, T. (2013). Galectin-4, a Novel Predictor for Lymph Node Metastasis in Lung Adenocarcinoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081883"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13402-012-0109-1","article-title":"Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients","volume":"36","author":"Barrow","year":"2013","journal-title":"Cell. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13402-013-0124-x","article-title":"Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer","volume":"36","author":"Kim","year":"2013","journal-title":"Cell. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ijc.25750","article-title":"Galectin-4 functions as a tumor suppressor of human colorectal cancer","volume":"129","author":"Satelli","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pep.2015.09.026","article-title":"Recombinant expression, purification and preliminary biophysical and structural studies of C-terminal carbohydrate recognition domain from human galectin-4","volume":"118","author":"Rustiguel","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"20289","DOI":"10.1038\/srep20289","article-title":"Structural characterisation of human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol, lactose, 3\u2032-sulfo-lactose, and 2\u2032-fucosyllactose","volume":"6","author":"Leffler","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1111\/febs.13348","article-title":"Structural characterization of human galectin-4 C-terminal domain: Elucidating the molecular basis for recognition of glycosphingolipids, sulfated saccharides and blood group antigens","volume":"282","author":"Leffler","year":"2015","journal-title":"FEBS J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/dbio.1995.1078","article-title":"Galectin-7, a human 14-kDa S-lectin, specifically expressed in keratinocytes and sensitive to retinoic acid","volume":"168","author":"Magnaldo","year":"1995","journal-title":"Dev. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.2353\/ajpath.2010.090876","article-title":"Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells","volume":"176","author":"Demers","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/01.MP.0000037306.19083.28","article-title":"Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: Diagnostic and biological implications","volume":"15","author":"Rorive","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_124","first-page":"41","article-title":"Galectin-7: Will the lectin\u2019s activity establish clinical correlations in head and neck squamous cell and basal cell carcinomas?","volume":"24","author":"Cada","year":"2009","journal-title":"Histol. Histopathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/0008-5472.CAN-06-3891","article-title":"Galectin-7 in lymphoma: Elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model","volume":"67","author":"Demers","year":"2007","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.18632\/oncotarget.1219","article-title":"Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer","volume":"4","author":"Kim","year":"2013","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1158\/0008-5472.CAN-04-0985","article-title":"Suppression of tumor growth by galectin-7 gene transfer","volume":"64","author":"Ueda","year":"2004","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ijc.27764","article-title":"Roles of galectin-7 and S100A9 in cervical squamous carcinoma: Clinicopathological and in vitro evidence","volume":"132","author":"Zhu","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/0008-5472.CAN-06-3283","article-title":"Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species","volume":"67","author":"Matsui","year":"2007","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ygyno.2013.04.056","article-title":"Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix","volume":"131","author":"Tsai","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.18632\/oncotarget.2299","article-title":"Expression and functions of galectin-7 in ovarian cancer","volume":"5","author":"Labrie","year":"2014","journal-title":"Oncotarget"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1742-4658.2011.08414.x","article-title":"Inhibition mechanism of human galectin-7 by a novel galactose-benzylphosphate inhibitor","volume":"279","author":"Masuyer","year":"2012","journal-title":"FEBS J."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"40970","DOI":"10.18632\/oncotarget.5403","article-title":"Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin","volume":"6","author":"Vladoiu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7314\/APJCP.2016.17.2.455","article-title":"Roles of galectin-7 in cancer","volume":"17","author":"Kaur","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Si, Y., Wang, Y., Gao, J., Song, C., Feng, S., Zhou, Y., Tai, G., and Su, J. (2016). Crystallization of Galectin-8 Linker Reveals Intricate Relationship between the N-terminal Tail and the Linker. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122088"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1023\/B:GLYC.0000014086.38343.98","article-title":"Human galectin-8 isoforms and cancer","volume":"19","year":"2002","journal-title":"Glycoconj. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/glycob\/cwu054","article-title":"Galectin-8: A matricellular lectin with key roles in angiogenesis","volume":"24","author":"Troncoso","year":"2014","journal-title":"Glycobiology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20547","DOI":"10.1074\/jbc.M802495200","article-title":"Dimeric galectin-8 induces phosphatidylserine exposure in leukocytes through polylactosamine recognition by the C-terminal domain","volume":"283","author":"Stowell","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12104-015-9623-1","article-title":"NMR assignments of the C-terminal domain of human galectin-8","volume":"9","author":"Liu","year":"2015","journal-title":"Biomol. NMR Assign."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kumar, S., Frank, M., and Schwartz-Albiez, R. (2013). Understanding the specificity of human galectin-8c domain interactions with its glycan ligands based on molecular dynamics simulations. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059761"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4049\/jimmunol.179.2.1225","article-title":"The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation","volume":"179","author":"Ronen","year":"2007","journal-title":"J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12032-008-9122-7","article-title":"Evaluation of galectin-8 expression in thyroid tumors","volume":"26","author":"Savin","year":"2009","journal-title":"Med. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000328439","article-title":"Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder","volume":"87","author":"Kramer","year":"2011","journal-title":"Urol. Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","article-title":"Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium","volume":"17","author":"Barrow","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_145","first-page":"349","article-title":"Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma","volume":"35","author":"Liu","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"44654","DOI":"10.18632\/oncotarget.17963","article-title":"Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer","volume":"8","author":"Tiraboschi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_147","first-page":"861","article-title":"Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system","volume":"16","author":"Danguy","year":"2001","journal-title":"Histol. Histopathol."},{"key":"ref_148","first-page":"587","article-title":"Varied expression and localization of multiple galectins in different cancer cell lines","volume":"19","author":"Satelli","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.bbagen.2016.04.019","article-title":"Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM\/CD166) promotes its surface segregation on breast cancer cells","volume":"1860","author":"Ferragut","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1074\/jbc.272.10.6416","article-title":"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin\u2019s disease","volume":"272","author":"Schmitt","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/glycob\/12.3.191","article-title":"Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity","volume":"12","author":"Sato","year":"2002","journal-title":"Glycobiology"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200608-1243OC","article-title":"Galectin-9 inhibits CD44\u2013Hyaluronan interaction and suppresses a murine model of allergic asthma","volume":"176","author":"Katoh","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.cell.2005.09.041","article-title":"Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes","volume":"123","author":"Ohtsubo","year":"2005","journal-title":"Cell"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2443.2009.01287.x","article-title":"Intracellular galectin-9 activates inflammatory cytokines in monocytes","volume":"14","author":"Matsuura","year":"2009","journal-title":"Genes Cells"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ijc.10436","article-title":"Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance","volume":"99","author":"Kageshita","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1078-0432.CCR-04-0861","article-title":"Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer","volume":"11","author":"Irie","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.170.7.3631","article-title":"Galectin-9 induces apoptosis through the Calcium-Calpain-Caspase-1 pathway","volume":"170","author":"Kashio","year":"2003","journal-title":"J. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000058002","article-title":"Association of galectin-9 with eosinophil apoptosis","volume":"128","author":"Saita","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","article-title":"Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis","volume":"127","author":"Seki","year":"2008","journal-title":"Clin. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.4049\/jimmunol.181.11.7660","article-title":"Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-tim-3 interactions","volume":"181","author":"Nagahara","year":"2008","journal-title":"J. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.7314\/APJCP.2012.13.6.2503","article-title":"Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s004320000207","article-title":"Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures","volume":"127","author":"Lahm","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/0008-5472.CAN-12-1260","article-title":"A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease","volume":"73","author":"Laderach","year":"2013","journal-title":"Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.7314\/APJCP.2014.15.5.2145","article-title":"Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers","volume":"15","author":"Chan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0002-9440(10)61121-2","article-title":"Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas","volume":"160","author":"Terris","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1007\/s13277-015-3248-y","article-title":"Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma","volume":"36","author":"Fu","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bju.12499","article-title":"Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: A rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides","volume":"113","author":"Kawashima","year":"2014","journal-title":"BJU Int."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/15548627.2015.1063767","article-title":"The epithelial polarity regulator LGALS9\/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux","volume":"11","author":"Wiersma","year":"2015","journal-title":"Autophagy"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"17633","DOI":"10.1073\/pnas.1012424107","article-title":"Galectin-9 trafficking regulates apical-basal polarity in Madin\u2013Darby canine kidney epithelial cells","volume":"107","author":"Mishra","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1541-7786.MCR-10-0040","article-title":"Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia","volume":"8","author":"Kuroda","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s11427-017-9176-7","article-title":"The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy","volume":"60","author":"Yang","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbrc.2006.12.002","article-title":"Involvement of integrins, MAPK, and NF-\u03baB in regulation of the shear stress-induced MMP-9 expression in endothelial cells","volume":"353","author":"Sun","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"16797","DOI":"10.1074\/jbc.M115.661272","article-title":"Impact of exogenous galectin-9 on human T cells","volume":"290","author":"Lhuillier","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.3748\/wjg.v22.i18.4515","article-title":"Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer","volume":"22","author":"Peng","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1189\/jlb.1HI0316-134R","article-title":"Galectin-12 inhibits granulocytic differentiation of human NB4 promyelocytic leukemia cells while promoting lipogenesis","volume":"100","author":"Xue","year":"2016","journal-title":"J. Leukoc. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:50:45Z","timestamp":1760194245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/1\/210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["ijms19010210"],"URL":"https:\/\/doi.org\/10.3390\/ijms19010210","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]}}}